Abstract
Obesity is a major health problem and as a result, it is reasonable to consider pharmacological approaches alongside approaches involving diet, physical activity and lifestyle change. The currently available drugs, sibutramine and orlistat, result in modest, clinically worthwhile weight loss, with demonstrable improvements in co-morbidity, but do not meet the often unrealistic expectations of patients or health care professionals managing obese patients. There is insufficient data on efficacy or safety of other agents to support their use. Many new pharmacological approaches are under investigation. These include gut hormones, such a peptide YY (3-36) and cholecystokinin that normally signal satiety, and centrally acting agents such a serotonin agonists, the anticonvulsants topiramate and zonisamide, cannabinoid receptor antagonists and drugs that act on other peptide neurotransmitter systems such as NPY and the melanocortins. Given the multiple pathways that influence energy balance, it is likely that therapies targeting more than one control system may be required in the future to meet the expectations and needs of patients needing to lose weight for medical reasons.
Keywords: anti-obesity drugs, obesity, sibutramine, anticonvulsants topiramate, cannabinoid receptor antagonists
Current Drug Targets
Title: Clinical Evaluation of Anti-Obesity Drugs
Volume: 5 Issue: 3
Author(s): John Wilding
Affiliation:
Keywords: anti-obesity drugs, obesity, sibutramine, anticonvulsants topiramate, cannabinoid receptor antagonists
Abstract: Obesity is a major health problem and as a result, it is reasonable to consider pharmacological approaches alongside approaches involving diet, physical activity and lifestyle change. The currently available drugs, sibutramine and orlistat, result in modest, clinically worthwhile weight loss, with demonstrable improvements in co-morbidity, but do not meet the often unrealistic expectations of patients or health care professionals managing obese patients. There is insufficient data on efficacy or safety of other agents to support their use. Many new pharmacological approaches are under investigation. These include gut hormones, such a peptide YY (3-36) and cholecystokinin that normally signal satiety, and centrally acting agents such a serotonin agonists, the anticonvulsants topiramate and zonisamide, cannabinoid receptor antagonists and drugs that act on other peptide neurotransmitter systems such as NPY and the melanocortins. Given the multiple pathways that influence energy balance, it is likely that therapies targeting more than one control system may be required in the future to meet the expectations and needs of patients needing to lose weight for medical reasons.
Export Options
About this article
Cite this article as:
Wilding John, Clinical Evaluation of Anti-Obesity Drugs, Current Drug Targets 2004; 5 (3) . https://dx.doi.org/10.2174/1389450043490479
DOI https://dx.doi.org/10.2174/1389450043490479 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Angiotensin II Receptor Blocker: Possibility of Antitumor Agent for Prostate Cancer
Mini-Reviews in Medicinal Chemistry Clinical Implications of CYP2D6 Genetic Polymorphism During Treatment with Antipsychotic Drugs
Current Drug Targets Effects of ACE Inhibitors on Skeletal Muscle
Current Pharmaceutical Design Antiplatelet Therapy in TAVI: Current Clinical Practice and Recommendations
Current Pharmaceutical Design Tissue Factor/Factor FVII Complex Inhibitors in Cardiovascular Disease. Are Things Going Well?
Current Cardiology Reviews Human Pharmacogenetics in the Zanzibar Islands – The Beginning of the CYP2C8 Story in the Malaria World
Current Pharmacogenomics and Personalized Medicine Innate Immunity and the Heart
Current Pharmaceutical Design Machine Learning Based Support System for Students to Select Stream (Subject)
Recent Advances in Computer Science and Communications Preface [Hot Topic: Heparin and Heparinoids: Correlation between Structure and antithrombotic activity. Clinical Applications and Future Perspectives (Executive Editor: Carl P. Dietrich)]
Current Pharmaceutical Design Thrombin-Activatable Fibrinolysis Inhibitor
Current Medicinal Chemistry Translational Application of Combining Magnetic Resonance Imaging and Biomechanical Analysis in Carotid Plaque Vulnerability Assessment
Recent Patents on Medical Imaging Chemistry and Health Effects of Bioactive Compounds in Selected Culinary Aromatic Herbs
Current Nutrition & Food Science Antioxidative Activity, Polyphenolic Content and Anti-Glycation Effect of Some Thai Medicinal Plants Traditionally Used in Diabetic Patients
Medicinal Chemistry Acute Coronary Syndromes in Patients with Atrial Fibrillation and Heart Failure. Could Novel Oral Anticoagulants be the Solution of the Optimal Antithrombotic Therapy Puzzle?
Cardiovascular & Hematological Agents in Medicinal Chemistry Reduced Risk of Incident AD with Elective Statin Use in a Clinical Trial Cohort
Current Alzheimer Research Applications of FDG-PET/CT in Assessment of Vascular Infection and Inflammation
Current Molecular Imaging (Discontinued) Acute Coronary Syndrome and its Antithrombotic Treatment: Focus on Aspirin and Clopidogrel Resistance
Current Vascular Pharmacology Big Data and Genome Editing Technology: A New Paradigm of Cardiovascular Genomics
Current Cardiology Reviews The Journey of the Non-Vascular Relief for Migraine: From ‘Triptans’ To ‘Ditans’
Current Clinical Pharmacology Serendipity of Erythromycin in the Management of Periprosthetic Inflammation
Current Drug Therapy